• Publications
  • Influence
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
BACKGROUND Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and clinical activity against metastatic colorectal cancer, particularly inExpand
  • 7,187
  • 212
  • PDF
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.
PURPOSE To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. PATIENTS AND METHODS In a phase IIExpand
  • 1,815
  • 73
  • PDF
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
PURPOSE This phase II trial investigated the safety and efficacy of two doses of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, plus fluorouracil (FU)/leucovorin (LV)Expand
  • 1,626
  • 51
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
PURPOSE Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastaticExpand
  • 890
  • 41
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
BACKGROUND Although combination treatment with bevacizumab (humanized monoclonal antibody against vascular endothelial growth factor) and chemotherapy improves survival of patients with variousExpand
  • 800
  • 37
  • PDF
First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer
BACKGROUND Enhancing tumor‐specific T‐cell immunity by inhibiting programmed death ligand 1 (PD‐L1)–programmed death 1 (PD‐1) signaling has shown promise in the treatment of extensive‐stageExpand
  • 588
  • 33
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
PURPOSE In a phase III trial, combining bevacizumab (BV)--a recombinant, humanized, monoclonal antibody targeting vascular endothelial growth factor--with irinotecan, bolus fluorouracil (FU), andExpand
  • 665
  • 26
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
BACKGROUND Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and rearranged during transfection (RET) tyrosineExpand
  • 391
  • 21
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab
Bevacizumab (Avastin™; rhuMab VEGF), a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), significantly prolongs survival when added to intravenous 5‐fluorouracil‐basedExpand
  • 491
  • 19
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.
PURPOSE To describe the natural history of nonmetastatic prostate cancer and rising prostate-specific antigen (PSA) despite androgen deprivation therapy. PATIENTS AND METHODS The 201 patients inExpand
  • 373
  • 19